...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: New shares issued?
5
Aug 07, 2018 08:36AM
4
Aug 07, 2018 11:01AM
4
Aug 12, 2018 01:52PM
3
Aug 12, 2018 05:44PM
2
Aug 12, 2018 08:12PM
3
Aug 13, 2018 08:34AM
3
Aug 13, 2018 08:14PM
4
Aug 14, 2018 05:27AM
5
Aug 14, 2018 01:56PM

narmac - I too feel your frustration about liquidity and believe we will see some form of liquidity in the not to distant future. The ongoing Phase II trial is closing in on a year and a half that the Rockstars in the second cohort are about to achieve. Understanding that this is a very small sample size that time frame would represent about $9 billion of additional revenue for the pharma's that are providing the current standard of care medications for mCRPC. Sooner or later someone is going to blink in this standoff and we will end up with some jingle in our jeans. As for ZCC, the royalty Corp., the value is in the royalty which is currently a couple of years away. I think we can have our cake and eat it too in this case. Hang in there man it's not that far away.

All IMO dyodd 

tada

2
Aug 15, 2018 02:54PM
3
Aug 15, 2018 09:24PM
Share
New Message
Please login to post a reply